AFP and hepatocellular carcinoma: Among the HCC patients with normal preoperative AFP levels or without MVI, however, the median VAF in baseline ctDNA > 1% maintained good predictive performance for early tumor recurrence (HR, 5.4; P = 0.041 for the AFP normal group and HR, 18.3; P = 0.047 for non‐MVI group, respectively; Fig. 3C,D).